Brenzavvy (bexagliflozin)

BRENZAVVY is a medication that falls into the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is recommended as an addition to dietary and exercise measures to enhance the management of blood sugar levels in adults diagnosed with type 2 diabetes. Limitation of Use: This medication is not advisable for patients with type 1 diabetes. Its use in such cases may heighten the risk of a condition called diabetic ketoacidosis. 

Dosage And Administration: 

•  The suggested dose is 20 mg once daily, to be taken in the morning, with or without food. It’s essential not to crush or chew the tablet. 
•  Before starting BRENZAVVY, it is necessary to evaluate the patient’s kidney function and make corrections as needed. 
• This medication should not be used if the estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1.73 m². 

Ketoacidosis: Patients who exhibit signs and symptoms of metabolic acidosis should be assessed for ketoacidosis, regardless of their blood glucose levels. If ketoacidosis is suspected, the medication should be discontinued, and the patient should receive prompt evaluation and treatment. It is crucial to consider factors that may predispose patients to ketoacidosis before starting treatment, and some patients may require close monitoring and temporary discontinuation of therapy. 

Lower limb amputation: It is important to evaluate factors that might increase the risk of amputations before beginning treatment with BRENZAVVY. Patients should be monitored for signs and symptoms of infections or ulcers on their lower limbs, and the medication should be stopped if any such issues arise. 

Volume depletion: The use of BRENZAVVY may lead to acute kidney injury, particularly in patients with impaired kidney function, low systolic blood pressure, elderly patients, or those taking diuretics. It is advisable to assess and correct volume status in these patients before initiating the medication and to monitor for signs and symptoms during the course of treatment. 

Urosepsis and pyelonephritis: Patients should be evaluated for signs and symptoms of urinary tract infections and treated promptly if such infections are indicated. 

Hypoglycemia: Reducing the risk of hypoglycemia may require considering a lower dose of insulin or insulin secretagogues when they are used in combination with BRENZAVVY. 

Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Serious and potentially life-threatening cases of this condition have occurred in both male and female patients

treated with SGLT2 inhibitors. Patients experiencing pain, tenderness, redness, or swelling in the genital or perineal area, along with fever or malaise, should be assessed promptly, and appropriate treatment should be initiated. 

Genital mycotic infection: Monitoring for and treating genital fungal infections as necessary is advised. 

If you are considering the import of Elahere (Mirvetuximab Soravtansine) to India, please be aware that Elahere can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication: 

• Required Documentation for Import: 
•  A valid prescription from a qualified medical practitioner. 
• Diagnostic reports of the patient. 
• Government-issued identification proof for the patient, as recognized by the Government of India. 

Order Confirmation Process: 

The order for Elahere will be confirmed upon the receipt of the following documents: 

•  A valid prescription from a qualified doctor. 
• An import permit, if applicable. 
• Availability of Brenzavvy (bexagliflozin) in India: 

Brenzavvy (bexagliflozin) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia. 

Brenzavvy can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required. 

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Brenzavvy (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements. 

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe. 

Indian Pharma Network is proficient in sourcing Brenzavvy (bexagliflozin) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India. 

When was bexagliflozin FDA approved? 

On January 2023, FDA approved Brenzavvy. 

What is bexagliflozin used for? 

Bexagliflozin is used with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes. It works in the kidneys to prevent the absorption of glucose (blood sugar). This helps lower the blood sugar level. Bexagliflozin does not help patients who have insulin-dependent or type 1 diabetes. 

What is the brand name for bexagliflozin? 

Bexagliflozin, sold under the brand name Brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. 

What are side effects of brenzavvy? 

Frequent urination, dizziness, or lightheadedness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly. To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position. 

Does brenzavvy cause weight loss? 

Although BRENZAVVY has not received FDA approval for weight loss, modest decreases in weight were observed in clinical studies.